WALTHAM, Mass. / Oct 22, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company’s sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity’s continued evolution and strengthened commitments to creating a lasting, positive impact on the world.
“Whether it’s from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste and carbon emissions, we are making substantial strides in creating a healthier, cleaner and more inclusive world for generations to come,“ said Prahlad Singh, president and chief executive officer at Revvity. “The duly named Impact Report represents a purpose-driven shift for Revvity to a holistic, sustainable business approach – one that underlies our approach across the entire company.”
The report shares how the Company is positively impacting the environment and society through its responsible business philosophy and operations. Below are several highlights:
To learn more about Revvity’s commitments and progress visit esg.revvity.com.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Last Trade: | US$116.42 |
Daily Change: | -0.18 -0.15 |
Daily Volume: | 713,486 |
Market Cap: | US$14.170B |
December 17, 2024 November 19, 2024 November 19, 2024 November 04, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load